Cargando…
9-ING-41, a Small Molecule Inhibitor of GSK-3β, Potentiates the Effects of Chemotherapy on Colorectal Cancer Cells
Colorectal cancer (CRC) is one of the most common and lethal types of cancer. Although researchers have made significant efforts to study the mechanisms underlying CRC drug resistance, our knowledge of this disease is still limited, and novel therapies are in high demand. It is urgent to find new ta...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8696016/ https://www.ncbi.nlm.nih.gov/pubmed/34955846 http://dx.doi.org/10.3389/fphar.2021.777114 |
_version_ | 1784619711329206272 |
---|---|
author | Poloznikov, Andrey Nikulin, Sergey Bolotina, Larisa Kachmazov, Andrei Raigorodskaya, Maria Kudryavtseva, Anna Bakhtogarimov, Ildar Rodin, Sergey Gaisina, Irina Topchiy, Maxim Asachenko, Andrey Novosad, Victor Tonevitsky, Alexander Alekseev, Boris |
author_facet | Poloznikov, Andrey Nikulin, Sergey Bolotina, Larisa Kachmazov, Andrei Raigorodskaya, Maria Kudryavtseva, Anna Bakhtogarimov, Ildar Rodin, Sergey Gaisina, Irina Topchiy, Maxim Asachenko, Andrey Novosad, Victor Tonevitsky, Alexander Alekseev, Boris |
author_sort | Poloznikov, Andrey |
collection | PubMed |
description | Colorectal cancer (CRC) is one of the most common and lethal types of cancer. Although researchers have made significant efforts to study the mechanisms underlying CRC drug resistance, our knowledge of this disease is still limited, and novel therapies are in high demand. It is urgent to find new targeted therapy considering limited chemotherapy options. KRAS mutations are the most frequent molecular alterations in CRC. However, there are no approved K-Ras targeted therapies for these tumors yet. GSK-3β is demonstrated to be a critically important kinase for the survival and proliferation of K-Ras–dependent pancreatic cancer cells. In this study, we tested combinations of standard-of-care therapy and 9-ING-41, a small molecule inhibitor of GSK-3β, in CRC cell lines and patient-derived tumor organoid models of CRC. We demonstrate that 9-ING-41 inhibits the growth of CRC cells via a distinct from chemotherapy mechanism of action. Although molecular biomarkers of 9-ING-41 efficacy are yet to be identified, the addition of 9-ING-41 to the standard-of-care drugs 5-FU and oxaliplatin could significantly enhance growth inhibition in certain CRC cells. The results of the transcriptomic analysis support our findings of cell cycle arrest and DNA repair deficiency in 9-ING-41–treated CRC cells. Notably, we find substantial similarity in the changes of the transcriptomic profile after inhibition of GSK-3β and suppression of STK33, another critically important kinase for K-Ras–dependent cells, which could be an interesting point for future research. Overall, the results of this study provide a rationale for the further investigation of GSK-3 inhibitors in combination with standard-of-care treatment of CRC. |
format | Online Article Text |
id | pubmed-8696016 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86960162021-12-24 9-ING-41, a Small Molecule Inhibitor of GSK-3β, Potentiates the Effects of Chemotherapy on Colorectal Cancer Cells Poloznikov, Andrey Nikulin, Sergey Bolotina, Larisa Kachmazov, Andrei Raigorodskaya, Maria Kudryavtseva, Anna Bakhtogarimov, Ildar Rodin, Sergey Gaisina, Irina Topchiy, Maxim Asachenko, Andrey Novosad, Victor Tonevitsky, Alexander Alekseev, Boris Front Pharmacol Pharmacology Colorectal cancer (CRC) is one of the most common and lethal types of cancer. Although researchers have made significant efforts to study the mechanisms underlying CRC drug resistance, our knowledge of this disease is still limited, and novel therapies are in high demand. It is urgent to find new targeted therapy considering limited chemotherapy options. KRAS mutations are the most frequent molecular alterations in CRC. However, there are no approved K-Ras targeted therapies for these tumors yet. GSK-3β is demonstrated to be a critically important kinase for the survival and proliferation of K-Ras–dependent pancreatic cancer cells. In this study, we tested combinations of standard-of-care therapy and 9-ING-41, a small molecule inhibitor of GSK-3β, in CRC cell lines and patient-derived tumor organoid models of CRC. We demonstrate that 9-ING-41 inhibits the growth of CRC cells via a distinct from chemotherapy mechanism of action. Although molecular biomarkers of 9-ING-41 efficacy are yet to be identified, the addition of 9-ING-41 to the standard-of-care drugs 5-FU and oxaliplatin could significantly enhance growth inhibition in certain CRC cells. The results of the transcriptomic analysis support our findings of cell cycle arrest and DNA repair deficiency in 9-ING-41–treated CRC cells. Notably, we find substantial similarity in the changes of the transcriptomic profile after inhibition of GSK-3β and suppression of STK33, another critically important kinase for K-Ras–dependent cells, which could be an interesting point for future research. Overall, the results of this study provide a rationale for the further investigation of GSK-3 inhibitors in combination with standard-of-care treatment of CRC. Frontiers Media S.A. 2021-12-09 /pmc/articles/PMC8696016/ /pubmed/34955846 http://dx.doi.org/10.3389/fphar.2021.777114 Text en Copyright © 2021 Poloznikov, Nikulin, Bolotina, Kachmazov, Raigorodskaya, Kudryavtseva, Bakhtogarimov, Rodin, Gaisina, Topchiy, Asachenko, Novosad, Tonevitsky and Alekseev. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Poloznikov, Andrey Nikulin, Sergey Bolotina, Larisa Kachmazov, Andrei Raigorodskaya, Maria Kudryavtseva, Anna Bakhtogarimov, Ildar Rodin, Sergey Gaisina, Irina Topchiy, Maxim Asachenko, Andrey Novosad, Victor Tonevitsky, Alexander Alekseev, Boris 9-ING-41, a Small Molecule Inhibitor of GSK-3β, Potentiates the Effects of Chemotherapy on Colorectal Cancer Cells |
title | 9-ING-41, a Small Molecule Inhibitor of GSK-3β, Potentiates the Effects of Chemotherapy on Colorectal Cancer Cells |
title_full | 9-ING-41, a Small Molecule Inhibitor of GSK-3β, Potentiates the Effects of Chemotherapy on Colorectal Cancer Cells |
title_fullStr | 9-ING-41, a Small Molecule Inhibitor of GSK-3β, Potentiates the Effects of Chemotherapy on Colorectal Cancer Cells |
title_full_unstemmed | 9-ING-41, a Small Molecule Inhibitor of GSK-3β, Potentiates the Effects of Chemotherapy on Colorectal Cancer Cells |
title_short | 9-ING-41, a Small Molecule Inhibitor of GSK-3β, Potentiates the Effects of Chemotherapy on Colorectal Cancer Cells |
title_sort | 9-ing-41, a small molecule inhibitor of gsk-3β, potentiates the effects of chemotherapy on colorectal cancer cells |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8696016/ https://www.ncbi.nlm.nih.gov/pubmed/34955846 http://dx.doi.org/10.3389/fphar.2021.777114 |
work_keys_str_mv | AT poloznikovandrey 9ing41asmallmoleculeinhibitorofgsk3bpotentiatestheeffectsofchemotherapyoncolorectalcancercells AT nikulinsergey 9ing41asmallmoleculeinhibitorofgsk3bpotentiatestheeffectsofchemotherapyoncolorectalcancercells AT bolotinalarisa 9ing41asmallmoleculeinhibitorofgsk3bpotentiatestheeffectsofchemotherapyoncolorectalcancercells AT kachmazovandrei 9ing41asmallmoleculeinhibitorofgsk3bpotentiatestheeffectsofchemotherapyoncolorectalcancercells AT raigorodskayamaria 9ing41asmallmoleculeinhibitorofgsk3bpotentiatestheeffectsofchemotherapyoncolorectalcancercells AT kudryavtsevaanna 9ing41asmallmoleculeinhibitorofgsk3bpotentiatestheeffectsofchemotherapyoncolorectalcancercells AT bakhtogarimovildar 9ing41asmallmoleculeinhibitorofgsk3bpotentiatestheeffectsofchemotherapyoncolorectalcancercells AT rodinsergey 9ing41asmallmoleculeinhibitorofgsk3bpotentiatestheeffectsofchemotherapyoncolorectalcancercells AT gaisinairina 9ing41asmallmoleculeinhibitorofgsk3bpotentiatestheeffectsofchemotherapyoncolorectalcancercells AT topchiymaxim 9ing41asmallmoleculeinhibitorofgsk3bpotentiatestheeffectsofchemotherapyoncolorectalcancercells AT asachenkoandrey 9ing41asmallmoleculeinhibitorofgsk3bpotentiatestheeffectsofchemotherapyoncolorectalcancercells AT novosadvictor 9ing41asmallmoleculeinhibitorofgsk3bpotentiatestheeffectsofchemotherapyoncolorectalcancercells AT tonevitskyalexander 9ing41asmallmoleculeinhibitorofgsk3bpotentiatestheeffectsofchemotherapyoncolorectalcancercells AT alekseevboris 9ing41asmallmoleculeinhibitorofgsk3bpotentiatestheeffectsofchemotherapyoncolorectalcancercells |